ClinicalTrials.gg
Not yet recruitingNCT06577376Updated Sep 5, 2024

A PhaseⅠ/Ⅱ Study of Simmitinib or Irinotecan Liposomes Combined With DP303c in Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma

A Phase 1/2 interventional study of DP303c and Simmitinib tablets in Localized Advanced or Metastatic Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma, Expressing Human Epidermal Growth Factor Receptor-2 (HER-2) and Disease Progression After Receiving at Least One and at Most Two Lines of Systemic Treatment in the Past, sponsored by Shanghai Runshi Pharmaceutical Technology Co., Ltd. Not yet recruiting. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-09-05.

Sponsored by Shanghai Runshi Pharmaceutical Technology Co., Ltd · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
252
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This study is divided into two parts: Cohort 1 and Cohort 2. Cohort 1 includes the dose escalation phase of DP303c combined with simmitinib, as well as the randomized controlled trial (RCT) phase of DP303c combined with simmitinib; Cohort 2 includes dose escalation/dose extension of DP303c combined with irinotecan liposomes, as well as RCT stage of DP303c combined with irinotecan liposomes.

02

Conditions studied

  • Localized Advanced or Metastatic Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma
  • Expressing Human Epidermal Growth Factor Receptor-2 (HER-2)
  • Disease Progression After Receiving at Least One and at Most Two Lines of Systemic Treatment in the Past
03

In context

Lead sponsor

Shanghai Runshi Pharmaceutical Technology Co., Ltd is the lead sponsor of 9 studies on the registry; 7 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

    1. Aged 18-75 (including) years old; 2. Gastric adenocarcinoma or gastroesophageal junction adenocarcinoma diagnosed by histology or cytology; 3. Disease progression after receiving one or two in the past (first-line treatment must be platinum/fluorouracil combination chemotherapy with or without ); 4. There should be at least one according to the (RECIST v1.1),; 5. expression status: 2+ to 3+(applicable to Cohort 1) or 1+(applicable to Cohort 2); 6. Adequate organ or bone marrow function

Exclusion Criteria:

  • *Eligibility Criteria:

Inclusion Criteria:

  1. Aged 18-75 (including) years old;
  2. Gastric adenocarcinoma or gastroesophageal junction adenocarcinoma diagnosed by histology or cytology;
  3. Disease progression after receiving one or two lines of systemic treatment in the past (first-line treatment must be platinum/fluorouracil combination chemotherapy with or without immune checkpoint inhibitors);
  4. There should be at least one measurable lesion according to the response evaluation criteria in solid tumors (RECIST v1.1),;
  5. HER2 expression status: 2+ to 3+(applicable to Cohort 1) or 1+(applicable to Cohort 2);
  6. Adequate organ or bone marrow function

Exclusion Criteria:

  1. Patients who have experienced toxicity during previous treatment with trastuzumab or trastuzumab biosimilars, resulting in permanent discontinuation of trastuzumab or trastuzumab biosimilars;
  2. Patients with a history of allergies to any component of DP303c and deemed severe by the researchers
  3. There is uncontrolled serosal fluid accumulation that requires frequent drainage or medical intervention;
  4. Active or uncontrolled ;
  5. Has a history of serious cardiovascular and cerebrovascular diseases;
  6. There was a peripheral neuropathy of grade ≥ 2 (refer to 5.0) prior to enrollment;
  7. History of gastrointestinal perforation and/or fistula within 6 months of first use of medication;
  8. Inability to swallow medication orally or presence of gastrointestinal diseases;
  9. Urine protein ≥++ and 24-hour urine protein quantification>1.0 g during screening period;
  10. There are eye diseases that require intervention, such as corneal diseases, retinal diseases, or active eye infections;
  11. Used strong inhibitors or CYP3A4 strong inducers 14 days before the first medication ;
  12. Used UGT1A1 strong inhibitor before first medication and wash-off period is less than 5 half-lives.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
252 participants (estimated)

Study arms

  • Experimental
    DP303c injection, dose level 1, Q3W + simmitinib tablets, dose level 1, D1-D21, Q4W

    DP303c injection, dose level 1, intravenous drip, Q3W + simmitinib tablets, dose level 1, oral, QD, taken for 3 weeks, discontinued for 1 week, Q4W

    Drug: DP303c · Drug: Simmitinib tablets

  • Experimental
    DP303c injection, dose level 1, Q3W + simmitinib tablets, dose level 2, D1-D21, Q4W

    DP303c injection, dose level 1, intravenous drip, Q3W + simmitinib tablets, dose level 2, oral, QD, taken for 3 weeks, discontinued for 1 week, Q4W

    Drug: DP303c · Drug: Simmitinib tablets

  • Experimental
    DP303c injection, dose level 1, Q2W + simmitinib tablets, dose level 2, D1-D21, Q4W

    DP303c injection, dose level 1, intravenous drip, Q2W + simmitinib tablets, dose level 2, oral, QD, taken for 3 weeks, discontinued for 1 week, Q4W

    Drug: DP303c · Drug: Simmitinib tablets

  • Experimental
    DP303c injection, dose level 2, Q3W + simmitinib tablets, dose level 2, D1-D21, Q4W

    DP303c injection, dose level 2, intravenous drip, Q3W + simmitinib tablets, dose level 2, oral, QD, taken for 3 weeks, discontinued for 1 week, Q4W

    Drug: DP303c · Drug: Simmitinib tablets

  • Experimental
    DP303c RP2D + irinotecan liposomes RP2D

    Drug: DP303c · Drug: Irinotecan liposomes

  • Active comparator
    Single agent chemotherapy chosen by researchers

    Single agent chemotherapy chosen by researchers: paclitaxel, docetaxel, or irinotecan

    Drug: Paclitaxel or docetaxel or irinotecan

Interventions

  • DrugDP303c

    DP303c is an antibody conjugate drug (ADC), composed of one anti-HER2 monoclonal antibody coupled to one MMAE via an enzyme specific linker

  • A novel small molecule inhibitor targeting fibroblast growth factor receptor (FGFR), vascular endothelial growth factor receptor (VEGFR2, KDR), and colony-stimulating factor 1 receptor (CSF-1R)

  • DrugIrinotecan liposomes

    A chemotherapy

  • DrugPaclitaxel or docetaxel or irinotecan

    Paclitaxel or docetaxel or irinotecan is used as a control.

06

What researchers measure

Primary outcomes

  1. Dose-limiting toxicity(DLT) occurrence and incidence

    Time frame: Up to approximately 36 months after the first participant is enrolled

  2. Adverse events (AE) occurrence and incidence

    Time frame: Up to approximately 36 months after the first participant is enrolled

  3. Objective response rate (ORR) per RECIST 1.1

    Time frame: Up to approximately 36 months after the first participant is enrolled

  4. Serious adverse events (SAE) occurrence and incidence

    Time frame: Up to approximately 36 months after the first participant is enrolled

Secondary outcomes

  1. Disease control rate (DCR) per RECIST 1.1

    Time frame: Up to approximately 36 months after the first participant is enrolled

  2. Duration of response (DoR) per RECIST 1.1

    Time frame: Up to approximately 36 months after the first participant is enrolled

  3. Progression free survival (PFS) per RECIST 1.1

    Time frame: Up to approximately 36 months after the first participant is enrolled

  4. Overall survival(OS)

    Time frame: Up to approximately 36 months after the first participant is enrolled

  5. Blood drug concentration of DP303c

    Time frame: Up to approximately 36 months after the first participant is enrolled

  6. Blood concentration of total anti-DP303c antibody

    Time frame: Up to approximately 36 months after the first participant is enrolled

  7. Positive incidence of anti-DP303c antibody (ADA)

    Time frame: Up to approximately 36 months after the first participant is enrolled

  8. HER2 expression level

    Time frame: Up to approximately 36 months after the first participant is enrolled

  9. Blood concentration of simmitinib

    Time frame: Up to approximately 36 months after the first participant is enrolled

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Aug 2024; primary completion for Aug 2026, 24 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 21, 2024
First posted
Aug 29, 2024
StartEst.
Aug 26, 2024
Primary completionEst.
Aug 26, 2026
CompletionEst.
Aug 26, 2027
Last update
Sep 5, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 5, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06577376
Lead sponsor
Shanghai Runshi Pharmaceutical Technology Co., Ltd
Responsible party
Sponsor
First posted
Aug 29, 2024
Start date
Aug 26, 2024 (estimated)
Primary completion
Aug 26, 2026 (estimated)
Completion
Aug 26, 2027 (estimated)
Last update
Sep 5, 2024

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Trastuzumab envedotin

Start the discussion